Sodium Orthovanadate Changes Fatty Acid Composition and Increased Expression of Stearoyl-Coenzyme A Desaturase in THP-1 Macrophages
- 217 Downloads
Vanadium compounds are promising antidiabetic agents. In addition to regulating glucose metabolism, they also alter lipid metabolism. Due to the clear association between diabetes and atherosclerosis, the purpose of the present study was to assess the effect of sodium orthovanadate on the amount of individual fatty acids and the expression of stearoyl-coenzyme A desaturase (SCD or Δ9-desaturase), Δ5-desaturase, and Δ6-desaturase in macrophages. THP-1 macrophages differentiated with phorbol 12-myristate 13-acetate (PMA) were incubated in vitro for 48 h with 1 μM or 10 μM sodium orthovanadate (Na3VO4). The estimation of fatty acid composition was performed by gas chromatography. Expressions of the genes SCD, fatty acid desaturase 1 (FADS1), and fatty acid desaturase 2 (FADS2) were tested by qRT-PCR. Sodium orthovanadate in THP-1 macrophages increased the amount of saturated fatty acids (SFA) such as palmitic acid and stearic acid, as well as monounsaturated fatty acids (MUFA)—oleic acid and palmitoleic acid. Sodium orthovanadate caused an upregulation of SCD expression. Sodium orthovanadate at the given concentrations did not affect the amount of polyunsaturated fatty acids (PUFA) such as linoleic acid, arachidonic acid, eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA). In conclusion, sodium orthovanadate changed SFA and MUFA composition in THP-1 macrophages and increased expression of SCD. Sodium orthovanadate did not affect the amount of any PUFA. This was associated with a lack of influence on the expression of FADS1 and FADS2.
KeywordsSodium orthovanadate Fatty acids Macrophage THP-1 Desaturase
Vanadium is a metal that forms numerous inorganic compounds and complexes with organic substances. They are the subject of growing interest among researchers thanks to their antitumor properties . All vanadium compounds are competitive inhibitors of protein tyrosine phosphatases (PTP) [2, 3]. In experiments on cancer cells, vanadium compounds inhibited cell cycle at checkpoints G0/G1, G1/S, and G2/M [4, 5, 6, 7, 8, 9]. This is partly related to the inactivation of PTP involved in the correct course of the cell cycle . Vanadium compounds also act pro-apoptotically on tumor cells [4, 5, 6, 7, 9]. In particular, they cause the opening of the mitochondrial permeability transition pore which initiates apoptosis . They also increase the expression of Bax and decrease the expression of Bcl-2, i.e., proteins regulating apoptosis . Vanadium compounds also inhibit the epithelial–mesenchymal transition, which inhibits the formation of tumor metastases . Due to these properties, they are intensively tested for use as antineoplastic drugs [1, 13].
There are also advanced studies on the potential use of vanadium compounds in the treatment of diabetes [14, 15]. Vanadium compounds, due to the inhibition of PTP, increase the phosphorylation of proteins on tyrosine residues. This causes changes in various signaling pathways. In particular, vanadium compounds by inhibiting PTP-1B cause an increase in phosphorylation of the insulin receptor [16, 17, 18, 19]. Thanks to this, they abolish insulin resistance and potentiate the effect of insulin. They also strengthen the signal transmission from the insulin receptor and inhibit phosphatase and tensin homolog (PTEN). PTEN is an enzyme that catalyzes a reverse reaction to that catalyzed by phosphatidylinositol 3-kinases (PI3K) . Nevertheless, vanadium compounds not only increase the action of insulin but also exert other acts than insulin. They can inhibit the activity of protein kinase A (PKA) which inhibits gluconeogenesis and lipolysis . Vanadium compounds, when compared with insulin, also have a more pro-mitogenic effect inter alia, by affecting the activity of mitogen-activated protein kinases (MAPK) cascades .
Previous studies carried out in vivo [23, 24, 25] and in vitro  confirm the antidiabetic and insulin-enhancing properties of vanadium compounds, in particular vanadyl sulfate (VOSO4), sodium orthovanadate (Na3VO4), and the organic derivatives: bis(ethylmaltolato)oxovanadium(IV) (BEOV) and bis(maltolato)oxovanadium(IV) (BMOV). These compounds reduce blood glucose levels in many ways. In the muscles, they increase the expression of GLUT4, which increases the absorption of glucose from the blood. In liver and muscle cells, vanadium compounds stimulate glycogen synthesis  and increase glucose processing via the glycolysis pathway [27, 28]. They also reduce the intensity of gluconeogenesis . Vanadium compounds also reduce cholesterol and LDL levels, which were very elevated in streptozotocin-induced  or alloxan-induced  diabetic rats. Vanadium compounds also cause an increase in the number of beta-cells in the pancreas of streptozotocin-induced diabetic rats [24, 25]. Clinical trials involving VOSO4 have shown that vanadium compounds can be used in therapy [32, 33, 34]. It was shown that at a blood concentration of approximately 4 μM (75 mg VOSO4 daily, route of administration: oral 5 mg/day/kg body weight VOSO4) was not toxic, even after 6-week therapy of patients with type 2 diabetes mellitus (T2DM) [33, 34] or supplementation with insulin through 2.5 years of therapy of patients with type 1 diabetes mellitus (T1DM) . In a higher dose (300 mg orally), it caused mild diarrhea and malaise . However, the therapeutic window for vanadium compounds is very narrow. Vanadium compounds in a dose above 30 mg/day/kg body weight are toxic, cause oxidative stress, and are harmful to the liver and kidneys. That has been proven in experiments on broilers  and on rats  and mice . Vanadium compounds accumulate in the acidic environment of mitochondria in the form of decavanadate, which disturbs the functioning of these organelles [37, 38].
Diabetes has not only increased blood glucose levels, but also increased levels of plasma lipids, such as total cholesterol, low-density lipids (LDL), and triglyceride (TAG) as demonstrated in streptozotocin-induced  or alloxan-induced  diabetic rats as well as in patients with T2DM . Increased blood glucose causes oxidative stress and inflammatory reactions in the blood vessels . This process, combined with an increased amount of lipids in the plasma, causes the formation of oxysterols which are accumulated in macrophages . This results in the formation of foam cells in the blood vessels and inflammation, resulting in atherosclerotic lesions. This increases the prevalence of atherosclerosis in patients with T2DM .
Macrophages play an important role in diseases associated with diabetes, such as nephropathy or diabetic retinopathy [43, 44, 45]. Infiltration and accumulation of these cells occur in the kidney and retina, especially in diabetes. In addition, elevated glucose levels result in macrophages producing and secreting various proinflammatory cytokines and reactive oxygen species (ROS) that contribute to the development of diabetic nephropathy and retinopathy.
An important role in the course of atherosclerosis is played by the macrophages and lipid metabolism in these cells. Therefore, the main objective of the study was to investigate the effect of selected vanadium compounds on the concentration of individual fatty acids and the expression of desaturases responsible for the formation of unsaturated bonds in fatty acids in macrophages. THP-1 macrophages grown with sodium orthovanadate at 1 μM and 10 μM were used for this purpose. These are the concentrations at which the vanadium compounds exhibit hypoglycemic properties and do not show toxic properties in humans and laboratory animals [32, 34, 46, 47, 48, 49].
Materials and Methods
THP-1 cells are a monocyte cell line commonly used in research on inflammatory reactions and atherosclerotic mechanisms [50, 51, 52, 53, 54]. Cultures of THP-1 cells (ATCC, Rockville, USA) were grown at 37 °C in 5% CO2 on RPMI-1640 medium (BIOMED-LUBLIN, Poland) with the addition of 10% FBS (ALAB, Poland), along with penicillin (40 U/ml) and streptomycin (40 mg/l) (Sigma–Aldrich, Poland). Cells with a viability of over 97% were placed into 6-well plates, 3 × 106 wells altogether. The number of cells and their viability were determined using a Bright Line Hemacytometer (Sigma–Aldrich, Poznań, Poland) and trypan blue staining . After inoculation, THP-1 monocytes were differentiated into macrophages by adding 100 nM phorbol 12-myristate 13-acetate (PMA) (carrier: DMSO) (Sigma–Aldrich, Poland) to the culture. After 24 h of incubation, the cells were washed with PBS (BIOMED-LUBLIN, Poland) and incubated in Na3VO4 (Sigma–Aldrich, Poland) (carrier: PBS). One micrometer and 10 μM Na3VO4 were used in the experiment. These concentrations were determined on the basis of in vitro studies on the antidiabetic properties [32, 34, 49, 56] and antineoplastic properties [4, 5, 6, 7] of vanadium compounds. Cells were incubated in a medium supplemented with FBS. After 48 h of incubation with Na3VO4, THP-1 macrophages were scraped from the plate. After centrifugation (4 °C, 800×g, 10 min), the supernatant was discarded and the obtained cell pellet was frozen at − 80 °C for further analysis.
Isolation and Analysis of Fatty Acid Concentration
The fatty acids from the collected cells were extracted using Folch mixture  (2:1, chloroform:methanol), and heneicosanoic acid (21:0) was added as an internal standard to the collected cells. The fatty acids were saponified and methylated with KOH and BF3 in methanol. Extraction of the obtained fatty acid methyl esters was then carried out with hexane. They were then analyzed by gas chromatography, with the use of an Agilent Technologies 7890A GC System (SUPELCOWAX™ 10 Capillary GC Column (15 m × 0.1 mm × 0.1 μm)) (Supelco, Bellefonte, PA, USA). The following chromatographic conditions were applied: from an initial temperature of 60 °C increasing at a rate of 40 °C/min to 160 °C, then increasing at a rate of 30 °C/min to 190 °C, and then increasing at a rate of 30 °C/min to 230 °C for 2.6 min, where it was maintained for 4.9 min. The total analysis took approximately 8 min. The gas flow rate was 0.8 ml/min; the carrier gas was comprised of hydrogen. The identification of fatty acids was done by comparing their retention times with those of commercially available standards. The fatty acid concentrations were determined based on standard curves and were expressed in mg/ml.
Quantitative Real-time Polymerase Chain Reaction
Quantitative analyses of mRNA expression of stearoyl-coenzyme A desaturase (SCD), fatty acid desaturase 1 (FADS1), and fatty acid desaturase 2 (FADS2) were performed by two-step reverse transcription PCR. Total RNA was extracted from cells using an RNeasy Kit (Qiagen, USA). cDNA was prepared from 1 μg of total cellular RNA in 20 μl of reaction volume using a FirstStrand cDNA synthesis kit and oligo-dT primers (Fermentas, USA). The quantitative assessment of mRNA levels was performed by real-time RT-PCR using an ABI 7500Fast instrument with Power SYBR Green PCR Master Mix reagent. Real-time conditions were as follows: 95 °C (15 s), 40 cycles at 95 °C (15 s), and 60 °C (1 min). According to melting point analysis, only one PCR product was amplified under these conditions. Each sample was analyzed in two technical replicates, and the mean Ct values were used for further analysis. The relative quantity of the target, normalized to the endogenous control GAPDH gene and relative to a calibrator, is expressed as 2−∆∆Ct (fold difference), where Ct is the threshold cycle, ∆Ct = (Ct of target genes) − (Ct of endogenous control gene), and ∆∆Ct = (∆Ct of samples for target gene) − (∆Ct of calibrator for the target gene). The following primer pairs were used: FADS1 forward: CCAACTGCTTCCGCAAAGAC, FADS1 reverse: GCTGGTGGTTGTACGGCATA, FADS2 forward: TGACCGCAAGGTTTACAACAT, FADS2 reverse: AGGCATCCGTTGCATCTTCTC, SCD forward: TTCCTACCTGCAAGTTCTACACC, SCD reverse: CCGAGCTTTGTAAGAGCGGT.
Determination of Protein Content in the Sample
The results of the fatty acid content in the cells were converted to the protein content on the sample, which was determined using a Micro BCA Protein Assay Kit (Thermo Scientific, Pierce Biotechnology, USA) and spectrophotometer (UVM340, ASYS). The determination used biscynchonia acid (BCA), which allows detection of Cu1+ copper ions formed during Cu2+ reduction by proteins in alkaline environment. As a result of the chelation reaction of two molecules of BCA acid with one Cu1+ copper ion, the sample becomes violet. The method is based on the measurement of absorbance of the test substance at a wavelength of 562 nm. There is a linear relationship between the increase in protein concentration and intensity of the color.
The obtained results were analyzed using the Statistica 10.0 software package. The arithmetical mean ± SD was calculated for each of the studied parameters. The distribution of results for individual variables was obtained with the Shapiro–Wilk W test. As most of the distributions deviated from the normal distribution, non-parametric tests were used for further analyses. To assess the differences between the groups studied, the non-parametric Kruskal–Wallis ANOVA followed by the Mann–Whitney U test was used. A probability at p ≤ 0.05 was considered statistically significant.
Sodium Orthovanadate Increased the Amount of Saturated Fatty Acids in THP-1 Macrophages
Sodium Orthovanadate Increased the Amount of Monounsaturated Fatty Acids in THP-1 Macrophages
Sodium Orthovanadate Did Not Affect the Amount of Polyunsaturated Fatty Acids in THP-1 Macrophages
Sodium Orthovanadate Increased the Expression of Stearoyl-Coenzyme A Desaturase
Vanadium compounds are tested as promising drugs against T2DM [14, 15]. In addition to the effects on glucose metabolism, vanadium compounds such as sodium orthovanadate or vanadyl sulfate also reduce plasma cholesterol and LDL [30, 31]. These effects are the result of stimulating glycolysis, glycogen synthesis, and fatty acid synthesis in the liver, muscles, and adipose tissue [28, 31, 49, 58].
In this study, we found that sodium orthovanadate changed the fatty acid composition in THP-1 macrophages, increasing the amount of palmitic and stearic acids, as well as oleic and palmitoleic acids. This is associated with increased expression and activity of fatty acid synthase (FAS) and Δ9-desaturase, enzymes responsible for SFA and MUFA biosynthesis. The results obtained in this work confirm numerous scientific reports. In a streptozotocin-induced diabetic rat model which caused deregulation of glucose and lipid metabolism enzymes as well as decreased expression and activity of FAS and acetyl-CoA carboxylase in the liver, an increased expression and activity of these enzymes after exposure to vanadium compounds was demonstrated [28, 31, 58]. This may result in increased plasma glucose uptake by various tissues and its incorporation into fatty acid metabolism, thereby normalizing blood glucose levels. In our study, sodium orthovanadate also increased the expression of SCD and hence the activity of Δ9-desaturase. The expression of this enzyme is significantly altered by insulin and therefore decreases in diabetes . Therefore, our results are consistent with the previously indicated insulin-enhancing property of vanadium compounds. This confirms the results by Arbo et al. where insulin increased the expression of SCD and thus the activity of Δ9-desaturase .
The present work is the first to show that in addition to the effects on the liver, muscle, and adipose tissue, macrophages under incubation conditions with vanadium compounds may participate in glucose uptake and incorporation into lipid metabolism pathways, thereby contributing to the normalization of blood glucose.
In this work, sodium orthovanadate did not affect the amount of any PUFA in THP-1 macrophages. This was associated with the lack of influence on the expression of FADS1 and FADS2, genes encoding Δ5-desaturase and Δ6-desaturase, respectively, i.e., enzymes involved in the conversion of α-linolenic acid to EPA, DPA, and DHA and linoleic acid to γ-linolenic acid and arachidonic acid. We were the first to investigate the effect of sodium orthovanadate on the expression of FADS1 and FADS2. The lack of effect on the expression of these enzymes to some extent contradicts the properties of vanadium compounds. In THP-1 macrophages, insulin increases the expression of FADS1 and FADS2 and hence the activity of enzymes they encode, i.e., Δ5-desaturase and Δ6-desaturase . In streptozotocin-induced diabetic rats, disorders in the action of insulin resulted in the reduced expression of Δ6-desaturase in the liver . However, a study by Mašek et al. showed that the expression of FADS2 does not change in diabetic rat liver . The reason for these results may be the very properties of vanadium compounds. In particular, vanadium compounds affect metabolism via insulin-like growth factor 1 receptor (IGF-1R) . Therefore, they have a more inductive effect on the proliferation of cells than insulin. Thanks to this action, vanadium compounds are more effective in increasing the expression of SCD, an enzyme involved in the proliferation of cells . Vanadium compounds to a lesser extent affect the expression of FADS1 and FADS2 than insulin, which has a greater effect on metabolism. Another significant factor was the concentration of sodium orthovanadate, since the expression of FADS1 and FADS2 was affected at the higher concentration used (10 μM).
The results of our work show that sodium orthovanadate can affect the mechanisms involved in the development of atherosclerosis. Increased SCD expression and increased Δ9-desaturase activity protect macrophages from the proinflammatory action of SFA [64, 65, 66]. Among other things, it reduces the activation of NLRP3 inflammasome and NF-κB and thus inflammatory reactions that are important in the development of atherosclerosis. Also, the increased expression and activity of this enzyme causes the efflux of cholesterol from macrophages . These processes protect against the development of atherosclerosis.
On the other hand, in the same model of THP-1 macrophages, sodium orthovanadate increased the synthesis of prostaglandin E2 (PGE2) with arachidonic acid . This may promote the development of atherosclerosis . In addition, the sodium orthovanadate–induced increase in the amount of fatty acids in THP-1 macrophages demonstrated in our work may be not beneficial. Increased accumulation of SFA may cause inflammatory reactions and uptake of oxidized low-density lipoprotein (oxLDL) [66, 70]. Increased accumulation of SFA in macrophages may disturb cholesterol metabolism in them  and contribute to the formation of atherosclerosis, where macrophages are an important link. The accumulation of cholesterol esters derived from lipoproteins is followed by the de-esterification of cholesterol and removal of free cholesterol from these cells . Low activity of FAS increases the process of removing free cholesterol from macrophages and thus slows down atherosclerosis .
Vanadium compounds generate ROS, which can consequently accelerate the development of atherosclerosis. As has been shown so far, vanadyl, a vanadium compound at the +4 oxidation state, is responsible for this process. It caused the oxidation of plasma lipids in in vitro and in vivo experiments [30, 74]. After entering the cytoplasm, vanadium compounds at the +5 oxidation state (vanadates, including sodium orthovanadate) are reduced by intracellular antioxidants to vanadium compounds at the +4 oxidation state to give ROS [75, 76]. The inorganic vanadium compounds at the +4 oxidation state undergo Fenton reaction to form ROS and vanadate at +5 oxidation state [77, 78]. A cycle is formed in which ROS is constantly generated, compounds that destructively affect various molecules in the cell and cause formation of oxLDL [70, 74, 79].
The compounds with a large number of double bonds are particularly sensitive to oxidation by ROS. An example of such compounds is PUFA. These fatty acids contain many double bonds in one molecule, making them susceptible to oxidation by ROS. Therefore, increasing the amount of PUFA fatty acids in macrophage cells may exacerbate oxidative stress in them [80, 81, 82]. In our study, sodium orthovanadate did not increase the amount of PUFA fatty acids in the studied macrophages. Due to the generation of ROS by vanadium compounds, the lack of effect on the amount of PUFA in cells appears to be a positive property of the vanadium compound tested.
Increased expression of SCD by sodium orthovanadate may intensify cancer mechanisms. During its intensive division, a tumor cell synthesizes its components, including fatty acids, hence the increased expression of SCD in tumors, e.g., observed in human hepatocellular carcinoma , anaplastic thyroid carcinoma , breast cancers , prostate cancers , or lung adenocarcinoma . The greater the SCD expression in a tumor, the worse the prognosis. Therefore, Δ9-desaturase inhibitors are being investigated as potential anticancer drugs [87, 88]. If vanadium compounds increase the expression of SCD, they also increase tumor growth.
In conclusion, sodium orthovanadate changed SFA and MUFA composition in THP-1 macrophages and increased expression of SCD. Sodium orthovanadate did not affect the amount of any PUFA. This was associated with the lack of influence on the expression of FADS1 and FADS2.
This study was supported by the statutory budget of the Department of Biochemistry and Medical Chemistry, Pomeranian Medical University.
- 1.Crans DC, Yang L, Haase A, Yang X (2018) Health benefits of vanadium and its potential as an anticancer agent. Met Ions Life Sci 18. https://doi.org/10.1515/9783110470734-015
- 3.Irving E, Stoker AW (2017) Vanadium compounds as PTP inhibitors. Molecules 22. https://doi.org/10.3390/molecules22122269
- 6.Wu Y, Ma Y, Xu Z, Wang D, Zhao B, Pan H, Wang J, Xu D, Zhao X, Pan S, Liu L, Dai W, Jiang H (2014) Sodium orthovanadate inhibits growth of human hepatocellular carcinoma cells in vitro and in an orthotopic model in vivo. Cancer Lett 351:108–116. https://doi.org/10.1016/j.canlet.2014.05.018 CrossRefGoogle Scholar
- 9.Roy S, Banerjee S, Chakraborty T (2018) Vanadium quercetin complex attenuates mammary cancer by regulating the P53, Akt/mTOR pathway and downregulates cellular proliferation correlated with increased apoptotic events. Biometals 31:647–671. https://doi.org/10.1007/s10534-018-0117-3 CrossRefGoogle Scholar
- 10.Liu TT, Liu YJ, Wang Q, Yang XG, Wang K (2012) Reactive-oxygen-species-mediated Cdc25C degradation results in differential antiproliferative activities of vanadate, tungstate, and molybdate in the PC-3 human prostate cancer cell line. J Biol Inorg Chem 17:311–320. https://doi.org/10.1007/s00775-011-0852-1 CrossRefGoogle Scholar
- 12.Petanidis S, Kioseoglou E, Domvri K, Zarogoulidis P, Carthy JM, Anestakis D, Moustakas A, Salifoglou A (2016) In vitro and ex vivo vanadium antitumor activity in (TGF-β)-induced EMT. Synergistic activity with carboplatin and correlation with tumor metastasis in cancer patients. Int J Biochem Cell Biol 74:121–134. https://doi.org/10.1016/j.biocel.2016.02.015 CrossRefGoogle Scholar
- 14.Treviño S, Díaz A, Sánchez-Lara E, Sanchez-Gaytan BL, Perez-Aguilar JM, González-Vergara E (2019) Vanadium in biological action: chemical, pharmacological aspects, and metabolic implications in diabetes mellitus. Biol Trace Elem Res 188:68–98. https://doi.org/10.1007/s12011-018-1540-6 CrossRefGoogle Scholar
- 18.Scior T, Mack HG, García JA, Koch W (2009) Antidiabetic Bis-Maltolato-OxoVanadium(IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B. Drug Des Dev Ther 2:221–231Google Scholar
- 23.Hussain Shah SZ, Naveed AK, Rashid A (2016) Effects of oral vanadium on glycaemic and lipid profile in rats. J Pak Med Assoc 66:1592–1596Google Scholar
- 25.Pirmoradi L, Noorafshan A, Safaee A, Dehghani GA (2016) Quantitative assessment of proliferative effects of oral vanadium on pancreatic islet volumes and beta cell numbers of diabetic rats. Iran Biomed J 20:18–25Google Scholar
- 26.Tsiani E, Bogdanovic E, Sorisky A, Nagy L, Fantus IG (1998) Tyrosine phosphatase inhibitors, vanadate and pervanadate, stimulate glucose transport and GLUT translocation in muscle cells by a mechanism independent of phosphatidylinositol 3-kinase and protein kinase C. Diabetes 47:1676–1686CrossRefGoogle Scholar
- 32.Soveid M, Dehghani GA, Omrani GR (2013) Long- term efficacy and safety of vanadium in the treatment of type 1 diabetes. Arch Iran Med 16:408–411Google Scholar
- 33.Willsky GR, Halvorsen K, Godzala ME 3rd, Chi LH, Most MJ, Kaszynski P, Crans DC, Goldfine AB, Kostyniak PJ (2013) Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patients. Metallomics 5:1491–1502. https://doi.org/10.1039/c3mt00162h CrossRefGoogle Scholar
- 36.Roberts GK, Stout MD, Sayers B, Fallacara DM, Hejtmancik MR, Waidyanatha S, Hooth MJ (2016) 14-day toxicity studies of tetravalent and pentavalent vanadium compounds in Harlan Sprague Dawley rats and B6C3F1/N mice via drinking water exposure. Toxicol Rep 3:531–538. https://doi.org/10.1016/j.toxrep.2016.05.001 CrossRefGoogle Scholar
- 50.Wang YC, Hu YW, Sha YH, Gao JJ, Ma X, Li SF, Zhao JY, Qiu YR, Lu JB, Huang C, Zhao JJ, Zheng L, Wang Q (2015) Ox-LDL upregulates IL-6 expression by enhancing NF-κB in an IGF2-dependent manner in THP-1 macrophages. Inflammation 38:2116–2123. https://doi.org/10.1007/s10753-015-0194-1 CrossRefGoogle Scholar
- 51.Sha YH, Hu YW, Gao JJ, Wang YC, Ma X, Qiu YR, Li SF, Zhao JY, Huang C, Zhao JJ, Lu JB, Kang CM, Zheng L, Wang Q (2015) Lipoxin A4 promotes ABCA1 expression and cholesterol efflux through the LXRα signaling pathway in THP-1 macrophage-derived foam cells. Int J Clin Exp Pathol 8:6708–6715Google Scholar
- 57.Folch J, Lees M, Sloane-Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497–509Google Scholar
- 64.Brown JM, Chung S, Sawyer JK, Degirolamo C, Alger HM, Nguyen T, Zhu X, Duong MN, Wibley AL, Shah R, Davis MA, Kelley K, Wilson MD, Kent C, Parks JS, Rudel LL (2008) Inhibition of stearoyl-coenzyme A desaturase 1 dissociates insulin resistance and obesity from atherosclerosis. Circulation 118:1467–1475. https://doi.org/10.1161/CIRCULATIONAHA.108.793182 CrossRefGoogle Scholar
- 65.Peter A, Weigert C, Staiger H, Rittig K, Cegan A, Lutz P, Machicao F, Häring HU, Schleicher E (2008) Induction of stearoyl-CoA desaturase protects human arterial endothelial cells against lipotoxicity. Am J Physiol Endocrinol Metab 295:E339–E349. https://doi.org/10.1152/ajpendo.00022.2008 CrossRefGoogle Scholar
- 67.Nakaya K, Ayaori M, Uto-Kondo H, Sotherden GM, Nishida T, Katamoto H, Miura Y, Takiguchi S, Yakushiji E, Iizuka M, Ogura M, Sasaki M, Yogo M, Komatsu T, Adachi T, Maruyama C, Ikewaki K (2013) Overexpression of stearoyl-coenzyme A desaturase 1 in macrophages promotes reverse cholesterol transport. Biochim Biophys Acta 1831:1402–1411. https://doi.org/10.1016/j.bbalip.2013.05.009 CrossRefGoogle Scholar
- 69.Chen L, Yang G, Monslow J, Todd L, Cormode DP, Tang J, Grant GR, DeLong JH, Tang SY, Lawson JA, Pure E, Fitzgerald GA (2014) Myeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice. Proc Natl Acad Sci U S A 111:6828–6833. https://doi.org/10.1073/pnas.1401797111 CrossRefGoogle Scholar
- 71.Afonso MS, Lavrador MS, Koike MK, Cintra DE, Ferreira FD, Nunes VS, Castilho G, Gioielli LA, Paula Bombo R, Catanozi S, Caldini EG, Damaceno-Rodrigues NR, Passarelli M, Nakandakare ER, Lottenberg AM (2016) Dietary interesterified fat enriched with palmitic acid induces atherosclerosis by impairing macrophage cholesterol efflux and eliciting inflammation. J Nutr Biochem 32:91–100. https://doi.org/10.1016/j.jnutbio.2016.01.005 CrossRefGoogle Scholar
- 81.Song EA, Kim H (2016) Docosahexaenoic acid induces oxidative DNA damage and apoptosis, and enhances the chemosensitivity of cancer cells. Int J Mol Sci 17. https://doi.org/10.3390/ijms17081257
- 82.Aguilar-Toral R, Fernández-Quintero M, Ortiz-Avila O, de la Paz LH, Calderón-Cortés E, Rodríguez-Orozco AR, Saavedra-Molina A, Calderón-Torres M, Cortés-Rojo C (2014) Characterization of the effects of a polyunsaturated fatty acid (PUFA) on mitochondrial bioenergetics of chronologically aged yeast. J Bioenerg Biomembr 46:205–220. https://doi.org/10.1007/s10863-014-9550-3 CrossRefGoogle Scholar
- 84.von Roemeling CA, Marlow LA, Pinkerton AB, Crist A, Miller J, Tun HW, Smallridge RC, Copland JA (2015) Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target. J Clin Endocrinol Metab 100:E697–E709. https://doi.org/10.1210/jc.2014-2764 CrossRefGoogle Scholar
- 85.Peck B, Schug ZT, Zhang Q, Dankworth B, Jones DT, Smethurst E, Patel R, Mason S, Jiang M, Saunders R, Howell M, Mitter R, Spencer-Dene B, Stamp G, McGarry L, James D, Shanks E, Aboagye EO, Critchlow SE, Leung HY, Harris AL, Wakelam MJO, Gottlieb E, Schulze A (2016) Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer Metab 4:6. https://doi.org/10.1186/s40170-016-0146-8 CrossRefGoogle Scholar
- 88.Imamura K, Tomita N, Kawakita Y, Ito Y, Ono K, Nii N, Miyazaki T, Yonemori K, Tawada M, Sumi H, Satoh Y, Yamamoto Y, Miyahisa I, Sasaki M, Satomi Y, Hirayama M, Nishigaki R, Maezaki H (2017) Discovery of novel and potent stearoyl coenzyme a desaturase 1 (SCD1) inhibitors as anticancer agents. Bioorg Med Chem 25:3768–3779. https://doi.org/10.1016/j.bmc.2017.05.016 CrossRefGoogle Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.